Список проголосовавших за комментарий " <table class="BriefingDataTable" border="0" cellspacing="0" cellpadding="0"><tr> <td class="tickerColumn"> </td> <td class="articleColumn">Xencor target raised to $33 at Wedbush; Outperform (26.65)Wedbush raises their XNCR tgt to $33 from $27. With one of the strongest balance sheets of any development stage biotech, XNCR is well positioned to move its growing pipeline to later stages and approval. Firm updates their market model in asthma and IgG4-RD and removing further financings from their model due to long runway guided to by company, which in aggregate increases tgt.</td> </tr></table>"